PL1853721T3 - Sposób określania wrażliwości na inhibitory CHK1 - Google Patents
Sposób określania wrażliwości na inhibitory CHK1Info
- Publication number
- PL1853721T3 PL1853721T3 PL06709785T PL06709785T PL1853721T3 PL 1853721 T3 PL1853721 T3 PL 1853721T3 PL 06709785 T PL06709785 T PL 06709785T PL 06709785 T PL06709785 T PL 06709785T PL 1853721 T3 PL1853721 T3 PL 1853721T3
- Authority
- PL
- Poland
- Prior art keywords
- chk1
- patient
- determining susceptibility
- chk1 inhibitors
- signal transduction
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65413105P | 2005-02-18 | 2005-02-18 | |
| EP06709785A EP1853721B1 (en) | 2005-02-18 | 2006-02-16 | Method for determining responsiveness to chk1 inhibitors |
| PCT/GB2006/000548 WO2006087557A1 (en) | 2005-02-18 | 2006-02-16 | METHOD FOR DETERMINING RESPONSIVENESS TO CHKl INHIBITORS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1853721T3 true PL1853721T3 (pl) | 2010-08-31 |
Family
ID=36295309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL06709785T PL1853721T3 (pl) | 2005-02-18 | 2006-02-16 | Sposób określania wrażliwości na inhibitory CHK1 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20080145358A1 (pl) |
| EP (1) | EP1853721B1 (pl) |
| JP (1) | JP2008530575A (pl) |
| KR (1) | KR20070107034A (pl) |
| CN (1) | CN101120096A (pl) |
| AT (1) | ATE464395T1 (pl) |
| AU (1) | AU2006215413B2 (pl) |
| BR (1) | BRPI0607798A2 (pl) |
| CA (1) | CA2598185A1 (pl) |
| CY (1) | CY1110076T1 (pl) |
| DE (1) | DE602006013604D1 (pl) |
| DK (1) | DK1853721T3 (pl) |
| ES (1) | ES2341796T3 (pl) |
| HR (1) | HRP20100313T1 (pl) |
| IL (1) | IL184873A0 (pl) |
| MX (1) | MX2007010073A (pl) |
| NO (1) | NO20074610L (pl) |
| NZ (1) | NZ556718A (pl) |
| PL (1) | PL1853721T3 (pl) |
| PT (1) | PT1853721E (pl) |
| SI (1) | SI1853721T1 (pl) |
| WO (1) | WO2006087557A1 (pl) |
| ZA (1) | ZA200706670B (pl) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2086580A2 (en) * | 2006-11-21 | 2009-08-12 | Merial Limited | Prime boost canine leishmania vaccine |
| US8173366B2 (en) | 2007-03-29 | 2012-05-08 | University of Pittsburgh—of the Commonwealth System of Higher Education | Genetic changes in ATM and ATR/CHEK1 as prognostic indicators in cancer |
| WO2008121766A1 (en) | 2007-03-29 | 2008-10-09 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Genetic changes in atm and atr/chek1 as prognostic indicators in cancer |
| GB0720113D0 (en) * | 2007-10-15 | 2007-11-28 | Cambridge Cancer Diagnostics L | Diagnostic, prognostic and predictive testing for cancer |
| JP5436786B2 (ja) * | 2008-03-06 | 2014-03-05 | オリンパス株式会社 | 細胞周期計測方法 |
| WO2010076887A1 (en) * | 2009-01-05 | 2010-07-08 | Banyu Pharmaceutical Co.,Ltd. | Predictive biomarkers useful for cancer therapy mediated by a wee1 inhibitor |
| WO2016126616A1 (en) | 2015-02-02 | 2016-08-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods and kits for measuring and quantifying dna double-stranded breaks using gamma-h2ax and h2ax |
| AU2017261353A1 (en) * | 2016-05-05 | 2018-11-08 | Nantomics, Llc | Checkpoint failure and methods therefor |
| WO2018030546A1 (ja) * | 2016-08-12 | 2018-02-15 | 日立化成株式会社 | 血中循環癌細胞を検出するための前処理剤 |
| WO2021042163A1 (en) * | 2019-09-03 | 2021-03-11 | The Council Of The Queensland Institute Of Medical Research | Methods and agents for determining patient status |
| EP4555325A2 (en) | 2022-07-13 | 2025-05-21 | Acrivon Therapeutics, Inc. | Methods and systems for treating disease using an atr/chk1 signaling pathway inhibitor |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001161398A (ja) * | 1999-12-06 | 2001-06-19 | Igaku Seibutsugaku Kenkyusho:Kk | タンパク質リン酸化酵素の活性測定方法およびタンパク質リン酸化酵素の活性測定キット |
| DK1585749T3 (da) * | 2003-01-09 | 2008-09-22 | Pfizer | Diazepinoindol-derivater som kinaseinhibitorer |
| MXPA05009885A (es) * | 2003-03-14 | 2005-12-05 | Astrazeneca Ab | Nuevas triazolonas fusionadas y los usos de las mismas. |
| EP2669377A3 (en) * | 2003-04-17 | 2015-10-14 | Alnylam Pharmaceuticals Inc. | Modified iRNA agents |
| ITMI20030821A1 (it) * | 2003-04-18 | 2004-10-19 | Internat Ct For Genetic En Gineering And | Polipeptidi chimerici e loro uso. |
| US20050207998A1 (en) * | 2003-07-21 | 2005-09-22 | Yaoping Lu | Caffeine salt complexes and methods for using the same in the prevention or treatment of cancer |
| CA2539320A1 (en) * | 2003-09-17 | 2005-03-31 | Icos Corporation | Use of chk1 inhibitors to control cell proliferation |
-
2006
- 2006-02-16 PL PL06709785T patent/PL1853721T3/pl unknown
- 2006-02-16 AT AT06709785T patent/ATE464395T1/de active
- 2006-02-16 BR BRPI0607798-6A patent/BRPI0607798A2/pt not_active IP Right Cessation
- 2006-02-16 PT PT06709785T patent/PT1853721E/pt unknown
- 2006-02-16 WO PCT/GB2006/000548 patent/WO2006087557A1/en not_active Ceased
- 2006-02-16 ES ES06709785T patent/ES2341796T3/es not_active Expired - Lifetime
- 2006-02-16 MX MX2007010073A patent/MX2007010073A/es active IP Right Grant
- 2006-02-16 DE DE602006013604T patent/DE602006013604D1/de not_active Expired - Lifetime
- 2006-02-16 SI SI200630659T patent/SI1853721T1/sl unknown
- 2006-02-16 JP JP2007555699A patent/JP2008530575A/ja active Pending
- 2006-02-16 HR HR20100313T patent/HRP20100313T1/hr unknown
- 2006-02-16 NZ NZ556718A patent/NZ556718A/en not_active IP Right Cessation
- 2006-02-16 EP EP06709785A patent/EP1853721B1/en not_active Expired - Lifetime
- 2006-02-16 CN CNA2006800052527A patent/CN101120096A/zh active Pending
- 2006-02-16 US US11/816,128 patent/US20080145358A1/en not_active Abandoned
- 2006-02-16 KR KR1020077018373A patent/KR20070107034A/ko not_active Ceased
- 2006-02-16 CA CA002598185A patent/CA2598185A1/en not_active Abandoned
- 2006-02-16 DK DK06709785.7T patent/DK1853721T3/da active
- 2006-02-16 AU AU2006215413A patent/AU2006215413B2/en not_active Ceased
-
2007
- 2007-07-26 IL IL184873A patent/IL184873A0/en unknown
- 2007-08-10 ZA ZA200706670A patent/ZA200706670B/xx unknown
- 2007-09-11 NO NO20074610A patent/NO20074610L/no not_active Application Discontinuation
-
2010
- 2010-06-09 CY CY20101100544T patent/CY1110076T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20100313T1 (hr) | 2010-07-31 |
| BRPI0607798A2 (pt) | 2010-06-22 |
| MX2007010073A (es) | 2007-10-10 |
| SI1853721T1 (sl) | 2010-06-30 |
| EP1853721A1 (en) | 2007-11-14 |
| HK1113059A1 (en) | 2008-09-19 |
| AU2006215413B2 (en) | 2010-10-07 |
| NO20074610L (no) | 2007-11-14 |
| ZA200706670B (en) | 2008-10-29 |
| CY1110076T1 (el) | 2015-01-14 |
| ATE464395T1 (de) | 2010-04-15 |
| WO2006087557A1 (en) | 2006-08-24 |
| DE602006013604D1 (de) | 2010-05-27 |
| AU2006215413A1 (en) | 2006-08-24 |
| DK1853721T3 (da) | 2010-06-14 |
| EP1853721B1 (en) | 2010-04-14 |
| JP2008530575A (ja) | 2008-08-07 |
| KR20070107034A (ko) | 2007-11-06 |
| IL184873A0 (en) | 2007-12-03 |
| CN101120096A (zh) | 2008-02-06 |
| NZ556718A (en) | 2010-10-29 |
| PT1853721E (pt) | 2010-06-08 |
| US20080145358A1 (en) | 2008-06-19 |
| CA2598185A1 (en) | 2006-08-24 |
| ES2341796T3 (es) | 2010-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200706670B (en) | Method for determining responsiveness to CHK1 inhibitors | |
| FR2855877B1 (fr) | Determination precoce des resultats de tests | |
| ATE438853T1 (de) | Diagnostische testvorrichtung | |
| EA201201640A1 (ru) | Способы определения устойчивости рака к ингибиторам гистондеацетилазы | |
| EP2015757A4 (en) | HYDROLYSERESISTENT, BOROYED THERAPEUTIC USES | |
| EP2114990A4 (en) | ASSOCIATED GENES AND PROTEIN EXPRESSION PROFILES ASSOCIATED WITH THE THERAPEUTIC EFFECT OF EGFR TK INHIBITORS | |
| EP2049505A4 (en) | ISOFORM SELECTIVE HDAC HEMMER | |
| EP1802766A4 (en) | METHOD FOR A GLOBAL COOLING AND FIBRINOLYSIS TEST | |
| BR112012007555A2 (pt) | biomarcadores para prever a sensibilidade e resposta de doenças mediadas por quinase de proteína ck2 a inibidores de ck2 | |
| EP1994172A4 (en) | METHOD FOR THE DIAGNOSIS AND / OR PREDICTION OF THE DEVELOPMENT OF ALLERGIC DISEASE AND AGENTS FOR TREATMENT AND / OR PREVENTING THEREOF | |
| FR13C0024I1 (fr) | Combinaisons antitumorales contenant vegf-trap et du 5fu ou un de ses derives | |
| EP1874301A4 (en) | Niacin receptor agonists, compositions containing such compounds and treatment methods | |
| DE602007010246D1 (de) | Verfahren zur blutgerinnungsbestimmung | |
| WO2003103481A3 (en) | Methods for detecting b. anthracis infection | |
| EP2035551A4 (en) | METHOD FOR IDENTIFYING ACTIVE CANDIDATES FOR FAT MOBILIZATION | |
| ATE333521T1 (de) | Detektion von vancomycin-resistenten enterococcus-subspezies | |
| WO2005113797A3 (en) | METHODS FOR DETECTING Lp-PLA2 ACTIVITY AND INHIBITION OF Lp-PLA2 ACTIVITY | |
| EP1929044A4 (en) | METHOD AND SAMPLE COMBINATIONS FOR MELANOMA DETECTION | |
| WO2010030857A3 (en) | Egfr inhibitor therapy responsiveness | |
| DE602004017317D1 (de) | Verwendung der proteine proteinase 3 (prn3) und leukozyten elastatse inhibitor (ileu) als marker für kolorektale karzinome | |
| WO2007047335A3 (en) | Methods for use with baff antagonists | |
| BRPI0515794A (pt) | processos para avaliar pacientes com leucemia mielóide aguda | |
| EP1931394A4 (en) | APOE4 DOMAIN INTERACTION HEMMER AND APPLICATION METHOD THEREFOR | |
| FR2880426B1 (fr) | Procede et dispositif pour la determination du point de fumee des hydrocarbures | |
| EP2102393A4 (en) | FOR PLATINATE COORDINATION COMPLEX-INDUCED OTOTOXICITY, PRE-DICTIVE POLYMORPHISMS |